Condensed Consolidated Interim Financial Statements as of June 30, 2017

Bayer Group
Consolidated Income Statements

 

 

Q2 2016

Q2 2017

 

H1 2016

H1 2017

 

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales

 

11,833

12,193

 

23,687

25,437

Cost of goods sold

 

(5,028)

(5,119)

 

(10,072)

(10,464)

Gross profit

 

6,805

7,074

 

13,615

14,973

Selling expenses

 

(3,092)

(3,175)

 

(5,980)

(6,188)

Research and development expenses

 

(1,122)

(1,165)

 

(2,231)

(2,323)

General administration expenses

 

(489)

(608)

 

(984)

(1,180)

Other operating income

 

159

271

 

362

446

Other operating expenses

 

(123)

(246)

 

(324)

(461)

EBIT1

 

2,138

2,151

 

4,458

5,267

Equity-method loss

 

(6)

(11)

 

(11)

(24)

Financial income

 

42

101

 

79

136

Financial expenses

 

(350)

(495)

 

(697)

(866)

Financial result

 

(314)

(405)

 

(629)

(754)

Income before income taxes

 

1,824

1,746

 

3,829

4,513

Income taxes

 

(431)

(417)

 

(905)

(1,012)

Income from continuing operations after income taxes

 

1,393

1,329

 

2,924

3,501

Income from discontinued operations after income taxes

 

55

148

 

105

247

Income after income taxes

 

1,448

1,477

 

3,029

3,748

of which attributable to noncontrolling interest

 

68

253

 

138

441

of which attributable to Bayer AG stockholders (net income)

 

1,380

1,224

 

2,891

3,307

 

 

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

 

 

From continuing operations

 

 

 

 

 

 

Basic

 

1.60

1.23

 

3.37

3.51

Diluted

 

1.60

1.23

 

3.37

3.51

From discontinued operations

 

 

 

 

 

 

Basic

 

0.07

0.17

 

0.13

0.28

Diluted

 

0.07

0.17

 

0.13

0.28

From continuing and discontinued operations

 

 

 

 

 

 

Basic

 

1.67

1.40

 

3.50

3.79

Diluted

 

1.67

1.40

 

3.50

3.79